CONNECTS Study Data Request

To promote data sharing and reuse, CONNECTS is making all study data publicly available for request at NHLBI BioData Catalyst (BDC). CONNECTS studies are completed at different times and we strive to release each study’s datasets shortly after the process of data cleaning, quality check, standardization, and harmonization to CONNECTS COVID-19 Therapeutic Trial Common Data Elements (CDEs). To request available study data sets, click the link in the “Data Request” column. All data is housed at BioData Catalyst and information can be found at the BioData Catalyst COVID-19 Data page. All data requests are managed by dbGAP using the links found below.

Study Number Study Name Data Request Status
ACTIV4a - V1.0 ACTIV IV ACUTE: Anti-thrombotics for Adults Hospitalized With COVID-19, Phase 1 - Heparin Released
ACTIV4a - V1.1 ACTIV IV ACUTE: Anti-thrombotics for Adults Hospitalized With COVID-19, Phase 2- P2Y12 Inhibitors Released
ACTIV4a - V1.2 ACTIV IV ACUTE: Anti-thrombotics for Adults Hospitalized With COVID-19, Phase 3 - Crizanlizumab, SGLT2i Expected Spring 2024
ACTIV4b COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Released
ACTIV4c COVID-19 Post-hospital Thrombosis Prevention Study Released
ACTIV4 Host Tissue NECTAR: Novel Experimental COVID Therapies Affecting Host Response TBD
ACTIV4 Mechanistic Studies Prothombotic Antiphosphlipid Antibodies in COVID-19 TBD
Antiphospholipid Antibodies in COVID-19 TBD
Convergence of Apoptosis and Innate Immunity in COVID-19 Immunothrombosis TBD
Mechanisms of Endotheliopathy in SARS-CoV-2 Infection TBD
SARS-CoV-2 Viremia is Associated with Endothelial Injury and Increased Thrombotic Risk TBD
Characterization of Fibrinolytic Homeostasis in COVID-19 TBD
TF Activation in COVID-19 Associated Coagulopathy TBD
Antibody Mediated Thromboinflammation in COVID-19 TBD
Platelet Activity and Effector Cell Properties in COVID-19 TBD
ACTIV4-BEACONS: COVID-19: Comprehensive Biomarker Analysis for Prediction of clinical course and patient treatment outcomes (COVID-BEACONS) in ACTIV-4 TBD
Fibrinolysis Shutdown Underlies Advanced ARDS due to COVID-19 TBD
Investigating the Relationship between Catecholamines, Renalase and Angiotensin II in the RAAS Pathway in COVID-19 Patients TBD
C3PO Clinical Trial of COVID-19 Convalescent Plasma in Outpatients Released
C4R: Collaborative Cohort of Cohorts for COVID-19 Research Atherosclerosis Risk in Communities (ARIC) Released
REasons for Geographic and Racial Differences in Stroke (REGARDS) Released
Framingham Heart Study (FHS) Released
Severe Asthma Research Program (SARP) Released
Northern Manhattan Study (NOMAS) Released
Genetic Epidemiology of COPD Study (COPDGene) Expected Early 2024
Coronary Artery Risk Development in Young Adults (CARDIA) Expected Early 2024
Multi-Ethnic Study of Atherosclerosis (MESA) Expected Early 2024
The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Expected Early 2024
Prevent Pulmonary Fibrosis (PrePF) Expected Early 2024
Hispanic Community Health Study/Study of Latinos (HCHS/SOL) TBD
Jackson Heart Study (JHS) TBD
Subpopulations and Intermediate Markers in COPD Study (SPIROMICS) TBD